Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.
Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.